A law passed in 2008 called the Genetic Information Nondiscrimination Act (GINA) prohibits employers and health insurers from requiring you to submit to genetic testing as a condition of employment or to receive health insurance (see this blog, June 2, 2008). It also prevents employers or health insurers from requiring you to answer questions about any previous DNA tests you may have had. GINA was designed to prevent discrimination based on genetic information about your future health risks. (Interestingly, GINA does not apply to life, disability, or long-term care insurance; see this blog, Apr. 17, 2014).
Now a bill introduced in the republication-controlled Congress is attempting to take away the protections written into GINA. H.R. 1313 would allow employers to ask employees intrusive questions about the employee's health, as well as about the health and any genetic tests they or their family members have undergone in the past. Although refusing to answer still can't be used against the employee in terms of employment, those who choose not to answer could be required to pay 30-50% more for their company-provided health insurance. In effect, H.R. 1313 would require employees to choose between privacy of their genetic information and the cost of their health insurance.
By the way, the definition of "family member" used originally in GINA and adopted by H.R. 1313 goes way beyond just parents or children. It extends to the fourth degree, meaning from great-great-grandparents to great-great-grandchildren, as well as generations of aunts, uncles, and cousins. H.R. 1313 could potentially expose your extended family's entire genetic history, to the extent that it is known.
I'd be wary of agreeing to any genetic tests if this bill passes. You can't answer what you don't know.
Monday, March 13, 2017
Friday, March 10, 2017
Colorectal Cancer is Increasing in Young Adults
Colorectal cancer is generally considered to be a cancer of older people - so much so that the current recommendation is for colorectal cancer screening (a colonoscopy) every ten years after the age of 50. Most cases of colorectal cancer occur in people over 6O. Overall, the incidence of colorectal cancer has started to decline. However, in recent years there has been a sharp rise in colorectal cancer in the young. According to a report published in the Journal of the National Cancer Institute, adults born around 1990 (now in their 20s) have twice the risk of colon cancer and four times the risk of rectal cancer as a person who was born around 1950 when they were in their 20s.
The reason for this startling increase in risk for young people is not known. To be fair, the actual risk of colorectal cancer for persons in their 20s is still very low; about 1 case/yr. (per 100,000 population), compared to the over 50 cases/yr for persons over 60. If you're young, it's probably not worth worrying about.
However, the trend toward an increase in risk for the young is of concern to scientists, if only because we don't understand why it is happening when overall risk across all age groups is declining. It's worth keeping an eye on. At the very least, physicians should not rule out the possibility of colorectal cancer in their younger patients. Perhaps persons who have a family history of colorectal cancer should consider being screened before age 50.
The reason for this startling increase in risk for young people is not known. To be fair, the actual risk of colorectal cancer for persons in their 20s is still very low; about 1 case/yr. (per 100,000 population), compared to the over 50 cases/yr for persons over 60. If you're young, it's probably not worth worrying about.
However, the trend toward an increase in risk for the young is of concern to scientists, if only because we don't understand why it is happening when overall risk across all age groups is declining. It's worth keeping an eye on. At the very least, physicians should not rule out the possibility of colorectal cancer in their younger patients. Perhaps persons who have a family history of colorectal cancer should consider being screened before age 50.
Tuesday, March 7, 2017
Bird Flu is On the Rise Again
A deadly type of bird flu known to be transmissible to humans, called H7N9, seems to be breaking out again this flu season in China. H7N9 has caused only modest outbreaks since 2013, the year it was first identified (see this blog, Apr. 17, 2013). The intensity of yearly H7N9 outbreaks peaked in 2014 and then seemed to decline in 2015 and 2016, leading some health officials to think that the worst was over. Not so, it seems. The current 2017 outbreak of H7N9 (which began in October, the typical start of the winter flu season) is the worst outbreak yet. According to the World Health Association (WHO), more than a third of all cases of H7N9 flu ever recorded have occurred during this year's outbreak, and flu season isn't over.
H7N9 bird flu is not easily transmitted from birds to humans, but it is quite virulent. The death rate from confirmed H7N9 infections in humans is nearly 40%. So far, there are no confirmed cases of human-to-human transmission. Health officials worry that if/when the virus mutates in a way that makes it easily transmissible between humans, we could face a worldwide pandemic.
For now, H7N9 outbreaks have been confined to China, where close contact with poultry is much more common than it is in this country. Are we prepared for a H7N9 bird flu pandemic? The short answer is "no". At the moment there is no vaccine against it. Let's hope that a change to human-to-human transmission of H7N9 doesn't develop anytime soon.
H7N9 bird flu is not easily transmitted from birds to humans, but it is quite virulent. The death rate from confirmed H7N9 infections in humans is nearly 40%. So far, there are no confirmed cases of human-to-human transmission. Health officials worry that if/when the virus mutates in a way that makes it easily transmissible between humans, we could face a worldwide pandemic.
For now, H7N9 outbreaks have been confined to China, where close contact with poultry is much more common than it is in this country. Are we prepared for a H7N9 bird flu pandemic? The short answer is "no". At the moment there is no vaccine against it. Let's hope that a change to human-to-human transmission of H7N9 doesn't develop anytime soon.
Thursday, March 2, 2017
Supreme Court Nominee Gorsuch Opposes Death With Dignity Laws
Judge Neil Gorsuch, president Trump's nominee to the U.S. Supreme Court, is not a supporter of death with dignity (also called medical aid in dying) laws. In his 2009 book entitled The Future of Assisted Suicide and Euthanasia he defends his position, writing "...all human beings are intrinsically valuable and the intentional taking of human life by private persons is always wrong."
Five states (Oregon, Washington, Vermont, Colorado, and California) currently have death with dignity laws, and several others are considering them. In general these laws allow a person to terminate his/her own life under certain very narrow circumstances, which generally include the presence of a terminal illness, adequate counseling, and the consent of a physician. The Supreme Court has not yet considered a case involving these laws, so for now the states can make their own decisions.
Not every state is likely to pass death with dignity laws; indeed, some state's legislatures or legal counsels actively oppose them. The deputy solicitor general of the state of Wisconsin, for one, is already thinking about strategies for opposing death with dignity laws, should one ever be challenged in the federal courts.
The first challenge to a death with dignity law in the Supreme Court is likely to have a friend in Justice Gorsuch, should he be confirmed by the U.S. Senate. Just sayin'.
Five states (Oregon, Washington, Vermont, Colorado, and California) currently have death with dignity laws, and several others are considering them. In general these laws allow a person to terminate his/her own life under certain very narrow circumstances, which generally include the presence of a terminal illness, adequate counseling, and the consent of a physician. The Supreme Court has not yet considered a case involving these laws, so for now the states can make their own decisions.
Not every state is likely to pass death with dignity laws; indeed, some state's legislatures or legal counsels actively oppose them. The deputy solicitor general of the state of Wisconsin, for one, is already thinking about strategies for opposing death with dignity laws, should one ever be challenged in the federal courts.
The first challenge to a death with dignity law in the Supreme Court is likely to have a friend in Justice Gorsuch, should he be confirmed by the U.S. Senate. Just sayin'.
Monday, February 27, 2017
Microdosing With LSD to Treat Depression?
There seems to be a lot interest these days in the possible use of hallucinogens for medical purposes. Last month I reported that in a clinical study, the hallucinogen found in "magic mushrooms" seemed to reduce the symptoms of depression and anxiety, specifically in cancer patients (see this blog, Jan. 9, 2017). Now it appears that very small doses of another potent hallucinogen, lysergic acid (LSD), are being used by some people as a self-cure for more common forms of anxiety and depression.
It's called "microdosing". The trend started with the publication of the 2011 book, The Psychedelic Explorer's guide: Safe, Therapeutic, and Sacred Journeys. More recently, microdosing moved into the mainstream, more or less, with the publication of one woman's memoir, entitled A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life.
Wow, who wouldn't want a better mood, marriage, and life!? To be fair, microdosing with halucinogens might actually have some positive effects. But skeptics such as Richard Friedman would say that it's not a good idea to self-treat depression with psychogenic drugs just because someone wrote a self-help book about it. Microdosing with hallucinogens is untested; it's not even in the preliminary clinical research stage. Anyone trying it is taking unknown risks.
It's called "microdosing". The trend started with the publication of the 2011 book, The Psychedelic Explorer's guide: Safe, Therapeutic, and Sacred Journeys. More recently, microdosing moved into the mainstream, more or less, with the publication of one woman's memoir, entitled A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life.
Wow, who wouldn't want a better mood, marriage, and life!? To be fair, microdosing with halucinogens might actually have some positive effects. But skeptics such as Richard Friedman would say that it's not a good idea to self-treat depression with psychogenic drugs just because someone wrote a self-help book about it. Microdosing with hallucinogens is untested; it's not even in the preliminary clinical research stage. Anyone trying it is taking unknown risks.
Wednesday, February 22, 2017
First Vaping, Now "Dripping"
A study by researchers at Yale University reveals that about a quarter of all Connecticut teenagers who have tried vaping have circumvented e-cigarettes' design to deliver a stronger and more potent nicotine experience. It's called "dripping"; instead of allowing the e-cigarette's wick to deliver a controlled amount of liquid to the cigarette's coils, the coil is exposed so that nicotine liquid can be dripped directly onto the hot coils, producing a much heavier nicotine vapor cloud.
Regulators aren't sure how to respond to this recent trend. Although e-cigarettes certainly aren't as harmful as cigarettes, their long-term harm (if any) is still not known simply because they haven't been around long enough. The concept of e-cigarettes has been around since the 1930s, but the first commercially successful product wasn't created until 2003. For a complete timeline of the development and regulation of e-cigarettes, see this file. I can't confirm or deny the accuracy of the timeline, but the file was compiled by a group called Consumer Advocates for Smoke-Free Alternatives Association, so please be aware of possible bias.
Regulators aren't sure how to respond to this recent trend. Although e-cigarettes certainly aren't as harmful as cigarettes, their long-term harm (if any) is still not known simply because they haven't been around long enough. The concept of e-cigarettes has been around since the 1930s, but the first commercially successful product wasn't created until 2003. For a complete timeline of the development and regulation of e-cigarettes, see this file. I can't confirm or deny the accuracy of the timeline, but the file was compiled by a group called Consumer Advocates for Smoke-Free Alternatives Association, so please be aware of possible bias.
Wednesday, February 15, 2017
Gaining Ground on Clostridium difficile Infections
One of the most dangerous of all gut bacteria is a bacterium called Clostridium difficile. C. difficile can cause diarrhea so severe that it can lead to death, especially in older patients in hospitals and nursing homes, in whom it is most common. To make matters worse, it is difficult to treat because it is resistant to most antibiotics. Although it is present in most people, its population is normally kept in check by the presence of other "good" bacteria, which tend to out-compete it. But when nearly all of a person's gut bacteria are wiped out, for example when the person is given antibiotics, C. difficile can reproduce explosively, overwhelming the body's defenses.
Although C. difficile was first identified over 80 years ago, it wasn't until this century, when a strain of C. difficile developed resistance to most antibiotics, that the bacterium became a serious clinical problem. In a 2015 study published in the New England Journal of Medicine, the Centers for Disease Control and Prevention (CDC) reported that in 2011, C. difficile infections caused about 15,000 deaths directly and contributed indirectly to another 14,000 deaths.
But now health officials are seeing signs that C. difficile infections may be on the decline. One of the key factors may be our more enlightened use of antibiotics; i.e., only when truly needed. By reducing the indiscriminate use of antibiotics, especially in hospitals and nursing homes, there have been fewer opportunities for C. difficile to gain a foothold. But there are other signs of hope, too. Several vaccines are in the works, and Merck has a new (and expensive) drug called Zinplava that is at partially effective at reducing recurrent infections. Even fecal transplants (to reintroduce competing bacteria; see this blog, Feb. 23, 2014) seem to help, though these are still just in the experimental stage.
Progress is being made, though sometimes it seems slow. All we can do is keep trying.
Although C. difficile was first identified over 80 years ago, it wasn't until this century, when a strain of C. difficile developed resistance to most antibiotics, that the bacterium became a serious clinical problem. In a 2015 study published in the New England Journal of Medicine, the Centers for Disease Control and Prevention (CDC) reported that in 2011, C. difficile infections caused about 15,000 deaths directly and contributed indirectly to another 14,000 deaths.
But now health officials are seeing signs that C. difficile infections may be on the decline. One of the key factors may be our more enlightened use of antibiotics; i.e., only when truly needed. By reducing the indiscriminate use of antibiotics, especially in hospitals and nursing homes, there have been fewer opportunities for C. difficile to gain a foothold. But there are other signs of hope, too. Several vaccines are in the works, and Merck has a new (and expensive) drug called Zinplava that is at partially effective at reducing recurrent infections. Even fecal transplants (to reintroduce competing bacteria; see this blog, Feb. 23, 2014) seem to help, though these are still just in the experimental stage.
Progress is being made, though sometimes it seems slow. All we can do is keep trying.
Subscribe to:
Posts (Atom)